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Polo-like kinase (Plk) 1 is overexpressed in many human malignancies including nasopharyngeal 
carcinoma, indicating its potential as a therapeutic target. Recently, using a simple cellular morphology-
based strategy, we have identified several novel effective siRNAs against Plk1 including Plk1 siRNA-
607. In this study, we further investigated the effects of Plk1 siRNA-607 in human nasopharyngeal 
carcinoma cell line, HNE-1. Real time RT-PCR and Western blot indicated that Plk1 siRNA-607 
transfection resulted in a significant inhibition in Plk1 expression in the HNE-1 cells. Furthermore, cell 
cycle, cell growth and apoptosis analysis clearly indicated that Plk1 siRNA-607 caused a dramatic 
mitotic cell cycle arrest followed by massive apoptotic cell death, and eventually resulted in a 
significant decrease in growth and viability of the nasopharyngeal carcinoma cells. Given that Plk1 has 
been widely accepted as a novel efficient target for cancer therapy, these results suggested that Plk1 
siRNA-607 could be further developed for the treatment of human nasopharyngeal carcinoma.  
 





Nasopharyngeal carcinoma is a highly prevalent cancer 
in Southeast Asia especially in Southern China (Parkin et 
al., 2005; Chou et al., 2008; Tao and Chan, 2007). It 
poses one of the serious health problems in China with 
an annual incidence of more than 20 cases per 100,000 
and approximately 100,000 new cases diagnosed 
annually (Tao et al., 2007). Despite recent advances in 
naso-pharyngeal carcinoma treatment, the prognosis for 
patients with nasopharyngeal carcinoma remains poor 
(Tao et al., 2007). Thus, more efforts are needed to 
develop novel therapeutic approaches for the treatment 
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Abbreviations: Plk1, Polo-like kinase 1; siRNA, short 
interfering RNA; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; PCR, polymerase chain reaction. 
Plk1 is the best-characterized member of the human 
polo-like kinase (Plk) family which is highly conserved 
from yeasts to mammals (Glover et al., 1998; Golsteyn et 
al., 1994; Strebhardt and Ullrich, 2006; Chopra et al., 
2010; Bu et al., 2008; Lan et al., 2010). Numerous 
studies have shown that Plk1 plays critical roles during 
mitosis and regulates many mitotic events, including 
centrosome maturation, spindle formation, and execution 
of cytokinesis (Strebhardt et al., 2006; Chopra et al., 
2010; Bu et al., 2008; Lan et al., 2010). Importantly, Plk1 
was also found to be up-regulated in a variety of human 
tumors, and thereby has prognostic value for several 
types of cancers including nasopharyngeal carcinoma 
(Strebhardt et al., 2006; Bu et al., 2008; Takai et al., 2005; 
Knecht et al., 1999). Moreover, a recent study has shown 
that Plk1 also mediates invasion process through 
extracellular matrix such as vimentin and beta1 integrin 
(Rizki et al., 2007). Consequently, Plk1 has emerged as 
an attractive cancer therapy target with several appro-
aches being evaluated, including small interfering RNA 
(siRNA) and small molecule inhibitors (Strebhardt et al., 
2006; Chopra et al.,  2010;  Bu  et  al.,  2008). Consistent  




with this notion,several studies have shown that depletion 
of Plk1 by RNA silencing inhibits cellular growth and 
induces apoptosis in some cancer cells but not in normal 
cells (Liu and Erikson, 2003; Spänkuch-Schmitt et al., 
2002; Reagan-Shaw and Ahmad, 2005; Liu et al., 2006). 
Additionally, several pharmacological small-molecule 
inhibitors also showed promising results in clinical trials 
(Strebhardt et al., 2006; Chopra et al., 2010; Lan et al., 
2010).  
Recently, we proposed and demonstrated a simple 
cellular morphology-based strategy for rapid screening 
effective siRNAs against Plk1 (Lan et al., 2010). Plk1 
siRNA-607 is one of the four newly identified effective 
siRNA against Plk1. In this study, we further investigated 
its effects in human nasopharyngeal carcinoma cell line, 
HNE-1. Our results show that Plk1 siRNA-607 signifi-
cantly inhibited the Plk1 expression, and subsequently 
resulted in mitotic arrest followed by massive apoptotic 
cell death, eventually leading to a significant decrease in 
cell viability.  
 
 
MATERIALS AND METHODS  
 
Cell culture  
 
Human nasopharyngeal carcinoma cell line, HNE-1, was main-
tained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, 
Carlsbad, CA) containing 10% heat-inactivated fetal bovine serum 
(FBS, Invitrogen) and penicillin (100 IU/ml)/streptomycin (100 
mg/ml). Cells were maintained at 37°C in a water-saturated 
atmosphere of 5% CO2 in air.  
 
 
Design and synthesis of Plk1 siRNA  
 
Plk1 mRNA reference sequence, NM_005030, was used as tem-
plate to design siRNA against Plk1. Several novel candidate siRNA 
sequences were chosen to undergo preliminary investigation. 
siRNAs were chemically synthesized by Shanghai GenePharma. 
The Plk1 siRNA-607 sequence was 5'-AUGAAGAUCUGGAGGU 






The Plk1 siRNA and the negative control siRNA were transfected 
into cells using Lipofectamine RNAiMAX reagent (invitrogen) 
according to the manufacturer’s instructions. Cells were collected 
and subjected to subsequent analysis 24 to 72 h after transfection. 
 
 
Cell growth and viability assay  
 
Trypan blue exclusion assay was used to determine the effects of 
Plk1 depletion on the cellular growth and viability. The method has 
been described in details previously (Bu et al., 2008).  
 
 
RNA isolation and RT-PCR  
 
Total RNA was prepared from the indicated cells using the TRIZOL 





cDNA was generated from 1 µg of total RNA using SuperScript II 
reverse transcriptase and random primers following the 
manufacturer's conditions (Invitrogen). Real time PCR was carried 
out by using the SYBR
® 
Premix Ex Taq™ (Perfect Real Time, 
TAKARA) following the manufacturer's instructions. The relative 
expression level of the Plk1 gene compared with that of the 
housekeeping gene, GAPDH, was calculated by the 2
―∆∆Ct
 method 
(Livak and Schmittgen, 2001). The primer sequences used were as 
follows: Plk1, 5’-GGCAACCTTTTCCTGAATGA-3’ and 5’-
AATGGACCACACATCCACCT-3’; GAPDH, 5'-ACCTGACCTGCCG 
TCTAGAA-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’. PCR 
products were also separated by a 2.0% agarose gel electro-
phoresis and checked by ethidium bromide staining.  
 
 
Immunoblotting analysis  
 
Following the transfection of cells with control or Plk1 siRNA, the 
cells were collected, and subjected to immunoblotting analysis. The 
method was also described in details previously (Bu et al., 2008). 
The primary antibodies used in this study are the monoclonal anti-
Plk1(A-1, Zymed, San Francisco, CA), polyclonal anti-Phospho-
Histone H3 (ser10) (Upstate, Lake Placid, NY), and polyclonal anti-
actin (20 to 33, Sigma) antibody.  
 
 
Cell cycle analysis 
 
Both floating and attached cells were collected by trypsin digestion 
and low speed centrifugation, washed with cold PBS, and subjected 
to cell cycle analysis on a FACScan flow cytometer as described in 





An annexin V-FITC apoptosis detection kit (BD Pharmingen) was 
used to detect early apoptotic activity according to the 
manufacturer’s instructions, with slight modifications. The cells were 
harvested, washed twice with ice-cold PBS, and resuspended in 
binding buffer. Annexin V-FITC and propidium iodide (PI) were then 
added and incubated for 15 min at room temperature in the dark. 





Design and synthesis of Plk1 siRNA  
 
In a preliminary experiment, several novel siRNAs against 
Plk1 were investigated for their ability to inhibit Plk1 
expression and cell proliferation in malignant cells 
(unpublished data). Based on these observations, Plk1 
siRNA-607 was chosen for further investigation in this 
study. The siRNA was purified by high-performance liquid 
chromatography (HPLC), and checked for purity and 
integrity by PAGE (20%) under denaturing conditions 
(Figure 1).  
 
 
Plk1 siRNA-607 inhibits proliferation and decreases 
viability in HNE-1 cells 
 
At first, we determined the effect of Plk1 siRNA-607 on 







Figure 1. Synthesis of Plk1 
siRNA-607. The siRNA was 
purified by high-performance 
liquid chromatography 
(HPLC), and checked for 
purity and integrity by PAGE 





cells,   HNE-1.  Real  time  RT-PCR  and   Western   blot 
analysis demonstrated that the Plk1 expression was 
significantly inhibited at both mRNA and protein levels 
after transfection, whereas the expression of GAPDH or 
actin was unchanged. The expression level of Plk1 was 
efficiently reduced by at least 90% 48 h after transfection 
(Figure 2). As indicated in Figure 3A, Plk1 siRNA-607 
strongly inhibited the growth rate of HNE-1 cells whereas 
control siRNA did not affect the cellular proliferation. We 
also examined the cellular viability by Trypan blue 
exclusion assay. As indicated in Figure 3B, compared 
with the control siRNA which showed very little effect on 
cell viability, Plk1 siRNA-607 significantly reduced the cell 
viability in HNE-1 cells. 
 
 
Morphology changes in Plk1 siRNA-607-transfected 
HNE-1 cells 
 
Simultaneously, we also observed the morphology 
change in Plk1 siRNA-607-transfected HNE-1 cells. The 
control cells showed a typical polygonal and intact appea-
rance, and a normal growth phenotype, whereas the   
Plk1-depleted HNE-1 cells displayed significant abnormal 




morphological changes (Figure 4). Twenty-four hours 
after Plk1 siRNA-607 transfection, cells partially detached 
from the culture plates and floated on the media with 
round shape, suggesting the cell cycle arrest at mitosis 
phase. Forty-eight hours after transfection, cells became 
less confluent, and completely detached from the culture 
plates forming floating aggregates, suggesting the 
significant growth inhibition and cell death (Figure 4).  
 
 
Plk1 siRNA-607 induces mitotic cell cycle arrest in 
HNE-1 cells 
 
To further investigate the mechanism of morphology 
changes in Plk1-depleted cells, we analyzed the effect of 
Plk1 siRNA-607 on cell cycle distribution using flow 
cytometry. As shown in Figure 5A, Plk1 siRNA-607 
induced an obvious increase in the percentage of cells 
with 4N DNA content. Twenty-eight hours after trans-
fection, approximately 67% of Plk1 siRNA-607-trans-
fected HNE-1 cells had a 4N DNA content compared with 
only 7.5% in control siRNA-transfected cells. The 
phosphorylation of histone H3 at ser10, a mitosis marker, 
was then checked to confirm the phenotype of mitotic 
arrest in Plk1 siRNA-607-transfected cells. As shown in 
Figure 5B, a significant accumulation of ser10 phosphory-
lated histone H3 was observed in Plk1 siRNA-607-
transfected HNE-1 cells, suggesting that Plk1 siRNA-607 
causes mitotic arrest in HNE-1 cells. Consistently, the 
expression of mitotic cyclin, cyclin B1, also significantly 
accumulated in Plk1 siRNA-607-transfected HNE-1 cells.  
 
 
Plk1 siRNA-607 induces apoptosis in HNE-1 cells  
 
Noticeably, forty-eight hours after transfection, about 15% 
of Plk1 siRNA-607-transfected cells displayed sub-G1 
DNA content, strongly suggesting the induction of 
apoptosis in HNE-1 cells (Figure 5A). To further confirm 
this phenotype, annexin V-FITC and PI double staining 
with flow cytometry was used to check apoptosis in Plk1-
depleted cells. As expected, approximately 17 and 21% 
of Plk1 siRNA-607-transfected cells displayed early 
apoptotic (FITC＋/PI
―
) and late apoptotic/secondary 
necrotic phenotype forty-eight hours after transfection, 
whereas only 4.1 and 4.3% of control cells had this 





Plk1 is highly expressed in a variety of human tumors 
and also has prognostic value in several types cancers, 
indicating its involvement in carcinogenesis and its 
potential as a therapeutic target (Strebhardt and Ullrich, 
2006; Chopra et al., 2010; Bu et al., 2008). In naso-
pharyngeal carcinoma, Knecht et al. (1999) reported  that  






Figure 2. Plk1 siRNA-607 inhibits Plk1 expression. HNE-1 cells were transiently transfected with the control siRNA and Plk1 
siRNA-607, respectively. Twenty-four and four-eight hours after transfection, total RNA and whole cell lysates were prepared and 
subjected to real time RT-PCR and immunoblotting, respectively. For RT-PCR, GAPDH was used as an internal control. For IB, 
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Figure 3. Plk1 siRNA-607 inhibits cell growth. (A) The effect of Plk1 siRNA-607 on cell growth. Following siRNA transfection, 
cells were collected and counted at the indicated time points. The Y axis represents average folds of increase in cell numbers. 
The error bar represents the standard error of three independent experiments. (B) The effect of Plk1 siRNA-607 on cell viability. 
Cell viability was measured using Trypan blue exclusion analysis as described in material and methods. Cell viability data are 
expressed as the percent viable cells out of the total number of cells. The error bar represents the standard error of three 




Plk1 mRNA is overexpressed in human head and neck 
tumors including nasopharyngeal carcinoma and the 
overexpression of Plk1 mRNA correlates to prognostic 
parameters and the survival of patients with head and 
neck cancer. In this study, we designed and synthesized 
a novel Plk1 siRNA, Plk1 siRNA-607, and investigated its 
effects in human nasopharyngeal carcinoma cell line, 
HNE-1.  
According  to  our   results,  the   newly  designed   Plk1 
siRNA, Plk1 siRNA-607, significantly inhibited the Plk1 
expression at both mRNA and protein levels, and 
subsequently caused growth retardation and apoptosis in 
HNE-1 cells. Furthermore, we also found that mitotic cell 
cycle arrest was the early events and the first major 
phenotype in Plk1 siRNA-607-transfected HNE-1 cells. 
Additionally, as shown by the appearance of a sub-G1 
population in cell cycle profiles, and the increase of 
annexin V-FITC positive cells, apoptosis was  the  second  








Figure 4. Morphology changes in HNE-1 cells. HNE-1 cells were transiently transfected 
with the control siRNA and Plk1 siRNA-607, respectively. Cellular morphology were 
observed under phase-contrasted microscope at the indicated times after siRNA 









Figure 5. Plk1 siRNA-607 induces mitotic cell cycle arrest. (A) FACS profiles. HNE-1 cells 
were transiently transfected with the control siRNA and Plk1 siRNA-607, respectively. Four-
eight hours after transfection, cells were collected, fixed by ethanol, stained with propidium 
iodide and subjected to FACS analysis. The positions and percentages of G1, G2/M, and sub-
G1 populations are shown. (B) Western blot analysis. Following siRNA transfection, whole cell 
lysates were prepared and subjected to immunoblotting. Equality of protein loading was 
confirmed by the expression of actin.  






Figure 6. Plk1 siRNA-607 induces apoptosis. HNE-1 cells were transiently transfected with the control siRNA and Plk1 
siRNA-607, respectively. Forty-eight hours after transfection, cells were collected, stained with annexin V-FITC and 









major phenotype observed in Plk1 siRNA-607-transfected 
HNE-1 cells. These results are consistent with our study 
and other previous reports observed in other cancer cells 
(Bu et al., 2008; Reagan-Shaw and Ahmad, 2005; Liu 
and Erikson, 2002). Notably, the author of this study and 
other author have also shown that depletion of Plk1 
causes defects in mitosis processes such as failure of 
cytokinesis, and disruption of mitotic cell cycle 
progression via the Cdc25C and cdc2/cyclin B1 positive 
feedback loop (Bu et al., 2008; Reagan-Shaw and 
Ahmad, 2005; Roshak et al., 2000). Thus, further studies 
are needed to clarify whether Plk1 depletion results in 
these mitotic defects via the similar molecular mechanism 
in nasopharyngeal carcinoma cells.  
Recently, Shi et al. (2010) also obtained similar results 
in another nasopharyngeal carcinoma cell line, C666-1. 
These results demonstrated that targeting Plk1 using 
siRNA caused significant inhibition of proliferation, mitotic 
catastrophe, and apoptosis. The effect of targeting Plk1 
using siRNA could be further enhanced by ionizing 
radiation both in vitro and in vivo. Combined with our 
present and other previous reports, it is not unreasonable 
to speculate that Plk1 may serve as a potential target in 
the treatment of human nasopharyngeal cancer (Shi et 
al., 2010; Strebhardt and Ullrich, 2006; Chopra et al., 
2010; Bu et al., 2008; Lan et al., 2010).  
In summary, our study clearly indicated that Plk1 
siRNA-607 can significantly inhibit Plk1 expression, and 
induces mitotic arrest and apoptosis in HNE-1 cells. 
Given that Plk1 has been widely accepted as a novel 
efficient target for cancer therapy, we believe that Plk1 
siRNA-607 could be further developed for the treatment 
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